Genomic Testing in the Clinic

Join Dr. Robert Reid and Dr. Sreeni Chittoor as they explore the revolutionary impact of genomic testing in redefining cancer treatment. We focus on advanced solid tumors, such as non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer, examining how these state-of-the-art technologies are leading to more personalized and effective treatment strategies.

NSCLC METex14 Skipping

In this episode of OncoTalks, Dr. David Waterhouse and Dr. Paul Conkling discuss NSCLC and the groundbreaking developments in treating patients with MET exon 14 (METex14) skipping mutations. We review the science behind these targeted therapies, their clinical applications, and the impact on patient outcomes.

Management & Proactive Care in EGFR+ mNSCLC Treatment

Welcome to episode three of three. In this episode, Dr. Alex Spira and Dr. Josh Zabari, both experts in thoracic oncology, delve into the common side effects experienced by patients undergoing treatment for locally Advanced or Metastatic EGFR+ Non-Small Cell Lung Cancer (NSCLC). They discuss the importance of early identification and management of these side effects to optimize patient care and prevent treatment discontinuation. Listen in to review strategies for addressing dermatologic and gastrointestinal toxicities, the role of multidisciplinary teams, and the significance of continuous communication with patients and caregivers.
 

Resistance Mechanisms in EGFR+ mNSCLC

Welcome to episode two of three, where Dr. John Hamack from MD Anderson Cancer Center and Dr. Millie Doss from Stanford University discuss the latest advancements and ongoing challenges in treating locally Advanced or Metastatic EGFR+ Non-Small Cell Lung Cancer (NSCLC). Explore the unmet needs in first-line therapy, the variety of resistance mechanisms, and the evolving landscape of treatment strategies.
 

Unmet Needs in EGFR+ mNSCLC

Welcome to episode one of three, where we dive deep into the challenges and advancements in managing locally Advanced or Metastatic EGFR+ Non-Small-Cell Lung Cancer (NSCLC). Join Dr. Mark Socinski, Executive Medical Director of the Advent Health Cancer Institute, and Dr. David Waterhouse from Oncology Hematology Care in Cincinnati, Ohio, as they discuss the importance of biomarker testing, the evolution of treatment strategies, and the impact of effective first-line therapies on patient outcomes.